ArticleHaematologica2024
Talquetamab in multiple myeloma.
Article in Haematologica, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 26 citations in OpenAlex.
- Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance.Science China. Life sciences · 2026Review
- Review
- Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myeloma.Bone marrow transplantation · 2026Article
- Talquetamab-Related Dysgeusia in Multiple Myeloma Compared to BCMA-Targeted Bispecifics and High-Dose Melphalan.Cancer medicine · 2025Article
- Review
- Emerging role of G protein-coupled receptor class C group 5 member D-directed immunotherapy in multiple myeloma: Advances, resistance and combination strategies.British journal of haematology · 2025Review
- Exploring the depths of hypogammaglobulinemia in lymphoid malignancies: Pathophysiology, clinical implications, management options, and future directions.Blood reviews · 2025Review
- METTL5 regulates SEPHS2-mediated selenoprotein synthesis to promote multiple myeloma survival and progression.Cell death & disease · 2025Article
- Real-world FDA database analysis unveiling cardiovascular adverse events associated with bispecific T cell engagers in multip myeloma.Scientific reports · 2025Article
- Polypharmacology: new drugs in 2023-2024.Pharmacological reports : PR · 2025Review
- From Molecular Precision to Clinical Practice: A Comprehensive Review of Bispecific and Trispecific Antibodies in Hematologic Malignancies.International journal of molecular sciences · 2025Review
- Global first-in-class drugs approved in 2023-2024: Breakthroughs and insights.Innovation (Cambridge (Mass.)) · 2025Review
- Talquetamab in Multiple Myeloma: Efficacy, Safety, and Future Directions.European journal of haematology · 2025Review
- The Use of Biologics for Targeting GPCRs in Metastatic Cancers.Biotech (Basel (Switzerland)) · 2025Review
- T-Cell Engagers In Multiple Myeloma: A Clinical Review.Blood and lymphatic cancer : targets and therapy · 2025Review
- The silent signals: emerging safety concerns in bispecific antibody therapy for multiple myeloma.Frontiers in medicine · 2025Article
- Revolutions at the frontline of multiple myeloma treatment: lessons and challenges to finding a cure.Frontiers in oncology · 2025Review
- Intracellular GPCR modulators enable precision pharmacology.npj drug discovery · 2025Review
- Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma.Current hematologic malignancy reports · 2024Review
- The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer.Nature communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Initial results of the phase I trial of talquetamab, a bispecific antibody targeting GPRC5D and CD3, were reported in December of 2022 for the treatment of relapsed or refractory multiple myeloma in the fourth line or later setting. It demonstrated a similar efficacy profile and durability of response to teclistamab, the first bispecific antibody therapy to be approved in multiple myeloma. Additionally, it has less infections than teclistamab but demonstrates unique class-specific side effects including skin, oral, and nail-related adverse events. Despite this, it is still a highly efficacious and well-tolerated therapy that will add to the armamentarium of therapeutics against heavily pretreated multiple myeloma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.